ANABAnaptysBio
About AnaptysBio
AnaptysBio (NASDAQ:ANAB) is a biotechnology company focused on advancing a pipeline of innovative antibody therapies aimed at addressing significant unmet medical needs in inflammation, immuno-oncology, and other diseases. Operating out of its base, the company leverages its proprietary somatic hypermutation (SHM) platform to discover and develop a range of novel antibodies. AnaptysBio's key projects include treatments for conditions such as severe inflammatory diseases and cancer, with several candidates currently undergoing clinical trials. The company's objectives center on bringing transformative therapeutic options to patients through meticulous research and development, while continuously expanding its portfolio of antibody therapeutics to improve patient outcomes in areas with critical healthcare needs.
What is ANAB known for?
Snapshot
Public US
Ownership
2005
Year founded
126
Employees
San Diego, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
San Diego, US
Products and/or services of AnaptysBio
- Immunotherapy drugs marketed to treat various inflammatory diseases including psoriasis, rheumatoid arthritis, and asthma.
- Custom antibody development services leveraging their proprietary platforms for pharmaceutical and biotechnology companies.
- Collaboration with large pharmaceutical companies to co-develop and co-commercialize novel immunotherapy treatments.
- Pipeline of experimental therapies aimed at treating autoimmune disorders through targeted immune modulation.
- Research and development in cancer immunotherapy, focusing on enhancing the efficacy of existing treatments.
- Advancement of bi-specific antibody technologies designed to address complex disease targets not amenable to traditional antibody approaches.
AnaptysBio executive team
- Mr. Daniel R. FagaPresident, CEO & Director
- Mr. Dennis M. MulroyChief Financial Officer
- Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.Chief Medical Officer
- Mr. Eric J. LoumeauChief Legal Officer
- Ms. Beth MuellerSenior Vice President of Human Resources
- Dr. Martin Dahl Ph.D.Senior Vice President of Research
- Mr. Benjamin StoneChief Business Officer
- Ms. Monique Da SilvaSenior Vice President of Corporate Affairs
- Ms. Priya RainaSenior Vice President of Clinical Operations
- Ms. Cailin Sibley FACR, M.D.Senior Vice President of Translational Medicine